nach oben

Current Geriatrics Reports

Erschienen in:

13.01.2018 | Neurology of Aging (K. Marder, Section Editor)

Recent Advances in Cholinergic Imaging and Cognitive Decline—Revisiting the Cholinergic Hypothesis of Dementia

verfasst von: Nicolaas I. Bohnen, Michel J. Grothe, Nicola J. Ray, Martijn L. T. M. Müller, Stefan J. Teipel

Erschienen in: Current Geriatrics Reports | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Although the cholinergic hypothesis of dementia provided a successful paradigm for the development of new drugs for dementia, this hypothesis has waned in popularity. Cholinergic brain imaging may provide novel insights into the viability of this hypothesis.

Recent Findings

Cholinergic receptor and forebrain volumetric studies suggest an important role of the cholinergic system in maintaining brain network integrity that may deteriorate with cognitive decline in Alzheimer disease (AD) and Lewy body disorders (LBD). Bidirectional changes in regional receptor expression may suggest the presence of compensatory responses to neurodegenerative injury. Cholinergic system changes are more complex in LBD because of additional subcortical degenerations compared to AD. Cholinergic-dopaminergic interactions affect attentional, verbal learning, and executive functions, and impairments in these two transmitter systems may jointly increase the risk of dementia in Parkinson’s disease.

Summary

The cholinergic hypothesis is evolving from a primary focus on memory toward expanded cognitive functions modulated by regionally more complex and interactive brain networks. Cholinergic network adaptation may serve as a novel research target in neurodegeneration.

Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol. 1974;30(2):113–21. https://doi.org/10.1001/archneur.1974.00490320001001.CrossRefPubMed

Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217(4558):408–14. https://doi.org/10.1126/science.7046051.CrossRefPubMed

Davies P, Maloney A. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;II:1403.CrossRef

Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet. 1977;309(I):189. https://doi.org/10.1016/S0140-6736(77)91780-9.CrossRef

Whitehouse PJ, Hedreen JC, White CL, Price DL. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol. 1983;13(3):243–8. https://doi.org/10.1002/ana.410130304.CrossRefPubMed

Arendt T, Bigl V, Arendt A, Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease. Acta Neuropathol (Berl). 1983;61(2):101–8. https://doi.org/10.1007/BF00697388.CrossRef

Hasselmo ME, Sarter M. Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology. 2011;36(1):52–73. https://doi.org/10.1038/npp.2010.104.CrossRefPubMed

Zemek F, Drtinova L, Nepovimova E, Sepsova V, Korabecny J, Klimes J, et al. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf. 2014;13(6):759–74. https://doi.org/10.1517/14740338.2014.914168.PubMed

Kalia LV. Biomarkers for cognitive dysfunction in Parkinson's disease. Parkinsonism Relat Disord. 2017;46:S19–23. https://doi.org/10.1016/j.parkreldis.2017.07.023.CrossRefPubMed

10.

Kalaitzakis ME, Pearce RK. The morbid anatomy of dementia in Parkinson's disease. Acta Neuropathol. 2009;118(5):587–98. https://doi.org/10.1007/s00401-009-0597-x.CrossRefPubMed

11.

Mesulam MM. The systems-level organization of cholinergic innervation in the human cerebral cortex and its alterations in Alzheimer's disease. Prog Brain Res. 1996;109:285–97. https://doi.org/10.1016/S0079-6123(08)62112-3.CrossRefPubMed

12.

Mesulam M, Mufson E, Levy A, Wainer B. Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol. 1983;214(2):170–97. https://doi.org/10.1002/cne.902140206.CrossRefPubMed

13.

Mesulam MM, Mufson EJ, Wainer BH, Levy AI. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (CH1-CH-6). Neurosci. 1983;10(4):1185–201. https://doi.org/10.1016/0306-4522(83)90108-2.CrossRef

14.

Heckers S, Geula C, Mesulam M. Cholinergic innervation of the human thalamus: dual origin and differential nuclear distribution. J Comp Neurol. 1992;325(1):68–82. https://doi.org/10.1002/cne.903250107.CrossRefPubMed

15.

Fibiger H. The organization and some projections of cholinergic neurons of the mammalian forebrain. Brain Res Rev. 1982;4(3):327–88. https://doi.org/10.1016/0165-0173(82)90011-X.CrossRef

16.

Mesulam M, Mash D, Hersh L, Bothwell M, Geula C. Cholinergic innervation of the human striatum, globus pallidus, subthalamic nucleus, substantia nigra, and red nucleus. J Comp Neurol. 1992;323(2):252–68. https://doi.org/10.1002/cne.903230209.CrossRefPubMed

17.

Shute CC, Lewis PR. Electron microscopy of cholinergic terminals and acetylcholinesterase-containing neurones in the hippocampal formation of the rat. Z Zellforsch Mikrosk Anat. 1966;69(1):334–43. https://doi.org/10.1007/BF00406286.CrossRefPubMed

18.

Herholz K, Weisenbach S, Zündorf G, Lenz O, Schröder H, Bauer B, et al. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. NeuroImage. 2004;21(1):136–43. https://doi.org/10.1016/j.neuroimage.2003.09.042.CrossRefPubMed

19.

Kuhl D, Minoshima S, Fessler J, Frey K, Foster N, Ficaro E, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol. 1996;40(3):399–410. https://doi.org/10.1002/ana.410400309.CrossRefPubMed

20.

Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology. 1999;52(4):691–9. https://doi.org/10.1212/WNL.52.4.691.CrossRefPubMed

21.

Kotagal V, Muller ML, Kaufer DI, Koeppe RA, Bohnen NI. Thalamic cholinergic innervation is spared in Alzheimer disease compared to parkinsonian disorders. Neurosci Lett. 2012;514(2):169–72. https://doi.org/10.1016/j.neulet.2012.02.083.CrossRefPubMedPubMedCentral

22.

• Richter N, Allendorf I, Onur OA, Kracht L, Dietlein M, Tittgemeyer M, et al. The integrity of the cholinergic system determines memory performance in healthy elderly. NeuroImage. 2014;100:481–8. https://doi.org/10.1016/j.neuroimage.2014.06.031. A MP4A-PET study highlighting the role of cholinergic system integrity for cognitive performance in the normal aging process CrossRefPubMed

23.

Haense C, Kalbe E, Herholz K, Hohmann C, Neumaier B, Krais R, et al. Cholinergic system function and cognition in mild cognitive impairment. Neurobiol Aging. 2012;33(5):867–77. https://doi.org/10.1016/j.neurobiolaging.2010.08.015.CrossRefPubMed

24.

Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti B, Davis JG, et al. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neurosci Lett. 2005;380(1–2):127–32. https://doi.org/10.1016/j.neulet.2005.01.031.CrossRefPubMed

25.

Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, et al. Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV. Mol Psychiatry. 2017;22(11):1531–8. https://doi.org/10.1038/mp.2017.183.CrossRefPubMed

26.

Liu AK, Chang RC, Pearce RK, Gentleman SM. Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease. Acta Neuropathol. 2015;129(4):527–40. https://doi.org/10.1007/s00401-015-1392-5.CrossRefPubMedPubMedCentral

27.

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197–211. https://doi.org/10.1016/S0197-4580(02)00065-9.CrossRefPubMed

28.

Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol. 2003;60(12):1745–8. https://doi.org/10.1001/archneur.60.12.1745.CrossRefPubMed

29.

Weintraub D, Somogyi M, Meng X. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis. Am J Alzheimers Dis Other Demen. 2011;26(6):443–9. https://doi.org/10.1177/1533317511424892.CrossRefPubMed

30.

Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K, et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. Brain. 2014;137(Pt 9):2493–508. https://doi.org/10.1093/brain/awu193.CrossRefPubMed

31.

• Mazere J, Lamare F, Allard M, Fernandez P, Mayo W. 123I-Iodobenzovesamicol SPECT imaging of cholinergic Systems in Dementia with Lewy bodies. J Nucl Med. 2017;58(1):123–8. https://doi.org/10.2967/jnumed.116.176180. Study demonstrating subcortical (striatal, thalamic, cerebellar) cholinergic transporters in DLB CrossRefPubMed

32.

Bohnen NI, Muller MLTM, Kotagal V, Koeppe RA, Kilbourn MR, Gilman S, et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J Cereb Blood Flow Metab. 2012;32(8):1609–17. https://doi.org/10.1038/jcbfm.2012.60.CrossRefPubMedPubMedCentral

33.

• Bohnen NI, Albin RL, Muller ML, Petrou M, Kotagal V, Koeppe RA, et al. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. JAMA Neurol. 2015;72(2):194–200. https://doi.org/10.1001/jamaneurol.2014.2757. A multitracer PET study showing both independent and interactive effects of cholinergic and dopaminergic degeneration on cognitive decline in Parkinson disease CrossRefPubMedPubMedCentral

34.

Sarter M, Albin RL, Kucinski A, Lustig C. Where attention falls: increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function. Exp Neurol. 2014;257C:120–9. https://doi.org/10.1016/j.expneurol.2014.04.032.CrossRef

35.

Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr, et al. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging. 2012;33(7):1203–14. https://doi.org/10.1016/j.neurobiolaging.2010.10.019.CrossRefPubMed

36.

Kucinski A, Paolone G, Bradshaw M, Albin RL, Sarter M. Modeling fall propensity in Parkinson's disease: deficits in the attentional control of complex movements in rats with cortical-cholinergic and striatal-dopaminergic deafferentation. J Neurosci. 2013;33(42):16522–39. https://doi.org/10.1523/JNEUROSCI.2545-13.2013.CrossRefPubMed

37.

Shah N, Frey KA, Muller MLTM, Petrou M, Kotagal V, Koeppe RA, et al. Striatal and cortical beta-Amyloidopathy and cognition in Parkinson's disease. Mov Disord. 2016;31(1):111–7. https://doi.org/10.1002/mds.26369.CrossRefPubMed

38.

• Kim K, Muller M, Bohnen NI, Sarter M, Lustig C. Thalamic cholinergic innervation makes a specific bottom-up contribution to signal detection: evidence from Parkinson's disease patients with defined cholinergic losses. NeuroImage. 2017;149:295–304. https://doi.org/10.1016/j.neuroimage.2017.02.006. Multitracer PET study demonstrating a unique role of thalamic cholinergic innervation (as opposed to cortical cholinergic or midbrain dopaminergic innervation) for bottom-up salience processing in the human brain CrossRefPubMed

39.

Buschman TJ, Miller EK. Top-down versus bottom-up control of attention in the prefrontal and posterior parietal cortices. Science. 2007;315(5820):1860–2. https://doi.org/10.1126/science.1138071.CrossRefPubMed

40.

•• Gratwicke J, Jahanshahi M, Foltynie T. Parkinson's disease dementia: a neural networks perspective. Brain. 2015;138(Pt 6):1454–76. https://doi.org/10.1093/brain/awv104. A comprehensive review and perspective article outlining possible links between neurotransmitter deficits, large-scale neural network dysfunction, and cognitive impairments in PD CrossRefPubMedPubMedCentral

41.

Meyer PM, Strecker K, Kendziorra K, Becker G, Hesse S, Woelpl D, et al. Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry. 2009;66(8):866–77. https://doi.org/10.1001/archgenpsychiatry.2009.106.CrossRefPubMed

42.

Kendziorra K, Wolf H, Meyer PM, Barthel H, Hesse S, Becker GA, et al. Decreased cerebral alpha4beta2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging. 2011;38(3):515–25. https://doi.org/10.1007/s00259-010-1644-5.CrossRefPubMed

43.

Dennis EL, Thompson PM. Functional brain connectivity using fMRI in aging and Alzheimer's disease. Neuropsychol Rev. 2014;24(1):49–62. https://doi.org/10.1007/s11065-014-9249-6.CrossRefPubMedPubMedCentral

44.

Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98(2):676–82. https://doi.org/10.1073/pnas.98.2.676.CrossRefPubMedPubMedCentral

45.

Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci. 2007;8(9):700–11. https://doi.org/10.1038/nrn2201.CrossRefPubMed

46.

• Colloby SJ, McKeith IG, Wyper DJ, O'Brien JT, Taylor JP. Regional covariance of muscarinic acetylcholine receptors in Alzheimer's disease using (R, R) [(123)I]-QNB SPECT. J Neurol. 2015;262(9):2144–53. https://doi.org/10.1007/s00415-015-7827-z. Study showing regional muscarinic cholinergic receptor changes overlapping with important brain networks subserving cognition in AD CrossRefPubMed

47.

Overk CR, Felder CC, Tu Y, Schober DA, Bales KR, Wuu J, et al. Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease. J Chem Neuroanat. 2010;40(1):63–70. https://doi.org/10.1016/j.jchemneu.2010.03.005.CrossRefPubMedPubMedCentral

48.

• Colloby SJ, Field RH, Wyper DJ, O'Brien JT, Taylor JP. A spatial covariance ¹²³I-5IA-85380 SPECT study of alpha4beta2 nicotinic receptors in Alzheimer's disease. Neurobiol Aging. 2016;47:83–90. https://doi.org/10.1016/j.neurobiolaging.2016.07.017. Study showing regional nicotinic cholinergic receptor changes overlapping with important brain networks subserving cognition in AD CrossRefPubMedPubMedCentral

49.

Iizuka T, Kameyama M. Cholinergic enhancement increases regional cerebral blood flow to the posterior cingulate cortex in mild Alzheimer's disease. Geriatr Gerontol Int. 2017;17(6):951–8. https://doi.org/10.1111/ggi.12818.CrossRefPubMed

50.

Seeley WW, Menon V, Schatzberg AF, Keller J, Glover GH, Kenna H, et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci. 2007;27(9):2349–56. https://doi.org/10.1523/JNEUROSCI.5587-06.2007.CrossRefPubMedPubMedCentral

51.

• Colloby SJ, McKeith IG, Burn DJ, Wyper DJ, O'Brien JT, Taylor JP. Cholinergic and perfusion brain networks in Parkinson disease dementia. Neurology. 2016;87(2):178–85. https://doi.org/10.1212/WNL.0000000000002839. Study showing regional muscarinic cholinergic receptor changes overlapping with important brain networks subserving cognition in PD CrossRefPubMedPubMedCentral

52.

• Isaias IU, Spiegel J, Brumberg J, Cosgrove KP, Marotta G, Oishi N, et al. Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson's disease. Front Aging Neurosci. 2014;6:213. https://doi.org/10.3389/fnagi.2014.00213. Study showing regional upregulation of nicotinic receptors in PD CrossRefPubMedPubMedCentral

53.

Hanyu H, Asano T, Sakurai H, Tanaka Y, Takasaki M, Abe K. MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia. AJNR Am J Neuroradiol. 2002;23(1):27–32.PubMed

54.

Choi SH, Jung TM, Lee JE, Lee SK, Sohn YH, Lee PH. Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status. Neurobiol Aging. 2012;33(7):1265–72. https://doi.org/10.1016/j.neurobiolaging.2010.11.015.CrossRefPubMed

55.

Ziegler DA, Wonderlick JS, Ashourian P, Hansen LA, Young JC, Murphy AJ, et al. Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease. JAMA Neurol. 2013;70(2):241–7. https://doi.org/10.1001/jamaneurol.2013.597.CrossRefPubMedPubMedCentral

56.

Teipel SJ, Flatz WH, Heinsen H, Bokde AL, Schoenberg SO, Stockel S, et al. Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain. 2005;128(Pt 11):2626–44. https://doi.org/10.1093/brain/awh589.CrossRefPubMed

57.

Grothe M, Heinsen H, Teipel SJ. Atrophy of the cholinergic basal forebrain over the adult age range and in early stages of Alzheimer's disease. Biol Psychiatry. 2012;71(9):805–13. https://doi.org/10.1016/j.biopsych.2011.06.019.CrossRefPubMed

58.

Teipel SJ, Meindl T, Grinberg L, Grothe M, Cantero JL, Reiser MF, et al. The cholinergic system in mild cognitive impairment and Alzheimer's disease: an in vivo MRI and DTI study. Hum Brain Mapp. 2011;32(9):1349–62. https://doi.org/10.1002/hbm.21111.CrossRefPubMed

59.

Grothe M, Zaborszky L, Atienza M, Gil-Neciga E, Rodriguez-Romero R, Teipel SJ, et al. Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease. Cereb Cortex. 2010;20(7):1685–95. https://doi.org/10.1093/cercor/bhp232.CrossRefPubMed

60.

•• Grothe MJ, Ewers M, Krause B, Heinsen H, Teipel SJ. Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. Alzheimers Dement. 2014;10(5):S344–53. https://doi.org/10.1016/j.jalz.2013.09.011. A combined MRI volumetry and amyloid-PET study demonstrating an in vivo association between cholinergic forebrain atrophy and cortical amyloid pathology in preclinical and predementia stages of AD that reproduces analogue findings from the neuropathologic literature.CrossRefPubMedPubMedCentral

61.

Whitwell JL, Weigand SD, Shiung MM, Boeve BF, Ferman TJ, Smith GE, et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain. 2007;130(Pt 3):708–19. https://doi.org/10.1093/brain/awl388.CrossRefPubMedPubMedCentral

62.

Teipel S, Heinsen H, Amaro E Jr, Grinberg LT, Krause B, Grothe M. Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease. Neurobiol Aging. 2014;35(3):482–91. https://doi.org/10.1016/j.neurobiolaging.2013.09.029.CrossRefPubMed

63.

Grothe MJ, Schuster C, Bauer F, Heinsen H, Prudlo J, Teipel SJ. Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia. J Neurol. 2014;261(10):1939–48. https://doi.org/10.1007/s00415-014-7439-z.CrossRefPubMed

64.

• Schmitz TW, Nathan SR. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology. Nat Commun. 2016;7:13249. https://doi.org/10.1038/ncomms13249. A serial MRI volumetry study showing that accelerated cholinergic forebrain degeneration precedes medial temporal lobe atrophy in the preclinical stage of AD CrossRefPubMedPubMedCentral

65.

Wolf D, Grothe M, Fischer FU, Heinsen H, Kilimann I, Teipel S, et al. Association of basal forebrain volumes and cognition in normal aging. Neuropsychologia. 2014;53:54–63. https://doi.org/10.1016/j.neuropsychologia.2013.11.002.CrossRefPubMed

66.

•• Grothe MJ, Heinsen H, Amaro E Jr, Grinberg LT, Teipel SJ. Cognitive correlates of basal forebrain atrophy and associated cortical Hypometabolism in mild cognitive impairment. Cereb Cortex. 2016;26(6):2411–26. https://doi.org/10.1093/cercor/bhv062. A combined MRI volumetry and glucose metabolic PET imaging study providing in vivo lesion evidence for cholinergic mediated neural networks subserving memory and attention in the human brain CrossRefPubMed

67.

Chalfonte BL, Johnson MK. Feature memory and binding in young and older adults. Mem Cogn. 1996;24(4):403–16. https://doi.org/10.3758/BF03200930.CrossRef

68.

Butler T, Zaborszky L, Pirraglia E, Li J, Wang XH, Li Y, et al. Comparison of human septal nuclei MRI measurements using automated segmentation and a new manual protocol based on histology. NeuroImage. 2014;97:245–51. https://doi.org/10.1016/j.neuroimage.2014.04.026.CrossRefPubMedPubMedCentral

69.

Ray NJ, Metzler-Baddeley C, Khondoker MR, Grothe MJ, Teipel S, Wright P, et al. Cholinergic basal forebrain structure influences the reconfiguration of white matter connections to support residual memory in mild cognitive impairment. J Neurosci. 2015;35(2):739–47. https://doi.org/10.1523/jneurosci.3617-14.2015.CrossRefPubMedPubMedCentral

70.

Ranganath C, Ritchey M. Two cortical systems for memory-guided behaviour. Nat Rev Neurosci. 2012;13(10):713–26. https://doi.org/10.1038/nrn3338.CrossRefPubMed

71.

Gratwicke J, Kahan J, Zrinzo L, Hariz M, Limousin P, Foltynie T, et al. The nucleus basalis of Meynert: a new target for deep brain stimulation in dementia? Neurosci Biobehav Rev. 2013;37(10 Pt 2):2676–88. https://doi.org/10.1016/j.neubiorev.2013.09.003.CrossRefPubMed

72.

Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease Cochrane Database. Syst Rev. 2012;3:CD006504. https://doi.org/10.1002/14651858.CD006504.pub2.

73.

Behl P, Edwards JD, Kiss A, Lanctot KL, Streiner DL, Black SE, et al. Treatment effects in multiple cognitive domains in Alzheimer's disease: a two-year cohort study. Alzheimers Res Ther. 2014;6(4):48. https://doi.org/10.1186/alzrt280.CrossRefPubMedPubMedCentral

74.

Cavedo E, Grothe MJ, Colliot O, Lista S, Chupin M, Dormont D, et al. Reduced basal forebrain atrophy progression in a randomized donepezil trial in prodromal Alzheimer's disease. Sci Rep. 2017;7(1):11706. https://doi.org/10.1038/s41598-017-09780-3.CrossRefPubMedPubMedCentral

75.

Kuhn J, Hardenacke K, Lenartz D, Gruendler T, Ullsperger M, Bartsch C, et al. Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer's dementia. Mol Psychiatry. 2015;20(3):353–60. https://doi.org/10.1038/mp.2014.32.CrossRefPubMed

76.

• Lee JE, Cho KH, Song SK, Kim HJ, Lee HS, Sohn YH, et al. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2014;85(1):7–16. https://doi.org/10.1136/jnnp-2013-305062. A longitudinal clinical observation study providing first in vivo evidence that MRI-measured cholinergic forebrain atrophy may predict imminent conversion to dementia in Parkinson Disease patients with MCI CrossRefPubMed

77.

Berger-Sweeney J. The cholinergic basal forebrain system during development and its influence on cognitive processes: important questions and potential answers. Neurosci Biobehav Rev. 2003;27(4):401–11. https://doi.org/10.1016/S0149-7634(03)00070-8.CrossRefPubMed

78.

Woolf NJ. Cholinergic systems in mammalian brain and spinal cord. Prog Neurobiol. 1991;37(6):475–524. https://doi.org/10.1016/0301-0082(91)90006-M.CrossRefPubMed

79.

Ballinger EC, Ananth M, Talmage DA, Role LW. Basal forebrain cholinergic circuits and signaling in cognition and cognitive decline. Neuron. 2016;91(6):1199–218. https://doi.org/10.1016/j.neuron.2016.09.006.CrossRefPubMedPubMedCentral

80.

Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Koeppe RA, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005;76(3):315–9. https://doi.org/10.1136/jnnp.2004.038729.CrossRefPubMedPubMedCentral

81.

Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 2016;73(6):721–32. https://doi.org/10.1001/jamaneurol.2016.0580.CrossRefPubMedPubMedCentral

82.

Lauretani F, Meschi T, Ticinesi A, Maggio M. Brain-muscle loop in the fragility of older persons: from pathophysiology to new organizing models. Aging Clin Exp Res. 2017;29(6):1305–11. https://doi.org/10.1007/s40520-017-0729-4.CrossRefPubMed

83.

Bohnen NI, Muller ML, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 2009;73(20):1670–6. https://doi.org/10.1212/WNL.0b013e3181c1ded6.CrossRefPubMedPubMedCentral

84.

Bohnen NI, Frey KA, Studenski S, Kotagal V, Koeppe RA, Scott PJ, et al. Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology. 2013;81(18):1611–6. https://doi.org/10.1212/WNL.0b013e3182a9f558.CrossRefPubMedPubMedCentral

85.

Ikonomovic MD, Mufson EJ, Wuu J, Cochran EJ, Bennett DA, DeKosky ST. Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimers Dis. 2003;5(1):39–48. https://doi.org/10.3233/JAD-2003-5106.CrossRefPubMed

Titel: Recent Advances in Cholinergic Imaging and Cognitive Decline—Revisiting the Cholinergic Hypothesis of Dementia
verfasst von: Nicolaas I. Bohnen
Michel J. Grothe
Nicola J. Ray
Martijn L. T. M. Müller
Stefan J. Teipel
Publikationsdatum: 13.01.2018
Verlag: Springer US
Erschienen in: Current Geriatrics Reports / Ausgabe 1/2018
Elektronische ISSN: 2196-7865
DOI: https://doi.org/10.1007/s13670-018-0234-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Recent Advances in Cholinergic Imaging and Cognitive Decline—Revisiting the Cholinergic Hypothesis of Dementia

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Rehabilitation for Individuals with Dementia: Facilitating Success

Tai Chi Beyond Balance and Fall Prevention: Health Benefits and Its Potential Role in Combatting Social Isolation in the Aging Population

Epilepsy in the Elderly: Risk Factors and Management Approaches

Using Informant and Performance Screening Methods to Detect Mild Cognitive Impairment and Dementia

Aging and the Pelvic Floor

Correction to: Management of Osteoporotic and Neuropathic Ankle Fractures in the Elderly

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin